Title: A Study on Assessment of Relationship between Blood Glucose and Serum Lipids in Patients of Dyslipidemia Receiving Atorvastatin
Authors: Gauri Hari Kasabe, Smita Anand Tiwari, Balasaheb Baburao Ghongane
DOI: https://dx.doi.org/10.18535/jmscr/v5i2.112
Abstract
Background: Atorvastatin and Lovastatin the most commonly used lipid lowering impair glucose tolerance; Simvastatin reduces insulin secretion while Pravastatin has been shown to increase adiponectin, improving insulin sensitivity and inhibiting gluconeogenesis. For these reasons, in February 2012 the United States Food and Drug Administration mandated labeling changes for all statins except Pravastatin. Objective of the study was to study the relationship between blood glucose and serum lipids in patients of Dyslipidemia receiving Atorvastatin
Methods: A prospective, single center study that was conducted in of total of 60 subjects. Newly diagnosed patients suffering from dyslipidemia, according to NCEP ATP III Guidelines (National Cholesterol Education Program, Adult Treatment Panel III).These are divided in 2 groups (n= 30 each). GROUP 1-patients having dyslipidemia with type 2 Diabetes Mellitus and GROUP 2-patients having dyslipidemia without Diabetes Mellitus.
Conclusion: With the results of present study 10 mg/day of Atorvastatin for 6 months did not affect FBG or PPBG in Non-diabetic patients significantly, but there was a significant deterioration in the blood glucose control - fasting and post-prandial, in the diabetic patients after 6 months and 3 months of drug use respectively. Atorvastatin 10 mg is an effective hypolipidemic drug and has adequate lipid lowering effects in diabetic and non-diabetics.
Key Words: Atorvastatin, Dyslipidemia,bloodglucose,serum lipids, correlation.
References
1. Misra A, Luthra K, Vikram NK. Dyslipidemia in Asian Indians: Determi-nants and Significance. JAPI .February 2004 ;52 :137-142 (Abstract) Available at : http://www.ncbi.nlm.nih.gov/pubmed/15656049
2. Dean G. Smith. Epidemiology of Dyslipi-demia and Economic Burden on the Healthcare System. Am J Manag Care. 2007; 13: S68-S71 Available at: http://www.ajmc.com/journals/supplement/2007/2007-06 vol13-n3suppl/jun07-2502ps69-s71/
3. Chandra KS , Bansal M., Nair T., Iyengar SS ,Gupta R., Manchanda SC et al. Conse-nsus statement on management of dyslip-idemia in Indian subjects. Indian heart journal. 2014; 66:S1-S51 Available at : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297876/
4. Carter AA ,Tara G, Ximena Camacho , Juurlink DN, Shah BR, Mamdani MM. Risk Of Incident Diabetes Among Patient Treated With Statin, A Population Based Study. BMJ 2013;346:f2610 doi: 10.1136/bmj.f2610 Available at : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662830/
5. US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. 2012. Available at : www.fda.gov/Drugs/DrugSafety/ucm293101.htm
6. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wacta-wski W et al. Statin use and risk of diabetes mellitus in postmenopausal wom-en in the Women’s Health Initiative. Arch Intern Med.2012;172:144-152 Available at : http://www.ncbi.nlm.nih.gov/pubmed/22231607
7. KatzungBG , Susan B. M, Antony. JT. Agents used in Dyslipidaemia. Basis & Clinical Pharmacology .11th edi .p: 605 – 607
8. BucoloG., David H.-Clin Chem. 1973,19,476. Esder T.W.,Michrina CA-Journal of biochemistry .Philadelphia PA.
9. Paul S. Jellinger, Donald Smith, Adi Mehta, Om Ganda, Yehuda Handelsman, Helena Rodbard, Mark Shepherd et al. American association of clinical endocrinologists’ guidelines for manage-ment of dyslipidemia and prevention of atherosclerosis, endocrine practice . 2012;18(supplement 1) Available at : http://journals.aace.com/doi/abs/10.4158/EP.18.S1.1?journalCode=endp
10. Alberti , Robert H. Eckel, Scott M. Grundy, Paul Z. Zimmet, James I. Cleeman, et al. Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity . Circulation. 2009;120:1640-1645. Available at : http://circ.ahajournals.org/content/120/16/1640.full.pdf+html
11. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34. Available at : http://www.nejm.org/doi/pdf/10.1056/NEJM199807233390404
12. Turner R, Cull C, Holman R. United Kingdom prospective diabetes study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin dependent diabetes mellitus. Ann Intern Med .1996 ; 124:136-45. Available at : http://annals.org/article.aspx?articleid=709358 (Abstract)
13. Chiquette E, Chilton R. Cardiovascular disease: much more aggressive in patients with type 2 diabetes. Curr Atheroscler Rep .2002; 4: 13442. Available at : http://link.springer.com/article/10.1007/s11883-0020037-z (Abstract)
14. Reaven GM, ChenY-DI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J ClinInvest .1993; 92:141–6. Available at : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC293550/pdf/jcinvest00028-0159.pdf
15. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol .1996; 7:167-71. Available at : http://www.ncbi.nlm.nih.gov/pubmed/8818515?dopt=Abstract
16. Tadashi Y,Tatsora T ,shun-ichi T , kazauki K ,Yasuo T . influence of pitavastatin on glucose tolerance in patients with type 2 diabetis mellitus. Journal of atherosclerosis and thrombosis .15(5) : 269-275. Available at : http://europepmc.org/abstract/MED/18981652 (Abstract)
17. Risto KH, Jorma SV, Saarimaa H . Correlation of Serum Lipids with Diabetes Control in Sulfonylurea-treated Diabetic Patients, diabetes care, november-december 1984 7( 6) : 575-579
18. Jun kasasi . Statins: beneficial or adverse for glucose metabolism .journal of athero-sclerosis and thrombosis. 2006 ; 13(3) :123-129 Available at : http://www.researchgate.net/publication/6951098_ Statins_Beneficial_orAdverse_ for_Glucose_Metabolism (Abstract)
19. Sukhija, Rishi, Prayaga, Sastry, Marashdeh, Mohammad et al . Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients, Journal of Investigative Medicine. March 2009 ; 57 (3) : 495499. Available at:http://journals.lww.com/jinvestigativemed/Abstract/2009/03000/Effect_ofStatins_on_Fasting_Plasma_Glucose_in.4.aspx (Abstract)
20. NaveedSattar , David Preiss, Heather M Murray, Paul Welsh, Brendan M Buckley, Anton JM de Craen et al . Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet . 27 February–5 March 2010 ; 375(9716) : 735–742. Available at http://www.thelancet.com/pdfs/journals/lancet/PIIS01406736%2809%2961965-6.pdf (Abstract)
21. HuptasS ,Geiss HC, Otto C, Parhofer KG. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.Am J Cardiol. 2006 Jul 1; 98(1):66-9. Available at : http://www.ncbi.nlm.nih.gov/pubmed/16784923 (Abstract)
22. Reddy AS ,Meera S , Ebenezer W, Kumar JS. Correlation between glycemic control and lipid profile in type 2 diabetic patients: hba1c as an indirect indicator of dyslipid-emia. Asian journal of pharmaceutical and clinical research. 2014; 7(2): 153-155. Available at : http://innovareacademics.in/journals/index.php/ajpcr/article/view/977 (Abstract)
23. Zhang L, Qiao Q, Tuomilehto J, Hammar N, Janus ED, Soderberg S et al. Blood lipid levels in relation to glucose status in seven populations of Asian origin without a prior history of diabetes: the DECODA study. Diabetes Metab Res Rev. 2009 Sep ; 25 (6): 549-57. Available at : http://onlinelibrary.wiley.com/doi/10.1002/dmrr.994/epdf